These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

859 related articles for article (PubMed ID: 24174625)

  • 1. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.
    Cervantes F; Vannucchi AM; Kiladjian JJ; Al-Ali HK; Sirulnik A; Stalbovskaya V; McQuitty M; Hunter DS; Levy RS; Passamonti F; Barbui T; Barosi G; Harrison CN; Knoops L; Gisslinger H;
    Blood; 2013 Dec; 122(25):4047-53. PubMed ID: 24174625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
    Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
    JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
    Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
    N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.
    Vannucchi AM; Kantarjian HM; Kiladjian JJ; Gotlib J; Cervantes F; Mesa RA; Sarlis NJ; Peng W; Sandor V; Gopalakrishna P; Hmissi A; Stalbovskaya V; Gupta V; Harrison C; Verstovsek S;
    Haematologica; 2015 Sep; 100(9):1139-45. PubMed ID: 26069290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis.
    Martí-Carvajal AJ; Anand V; Solà I
    Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD010298. PubMed ID: 25860512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
    Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger M; Miller C; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner E; Lyons RM; Paquette R; Raza A; Vaddi K; Erickson-Viitanen S; Koumenis IL; Sun W; Sandor V; Kantarjian HM
    N Engl J Med; 2012 Mar; 366(9):799-807. PubMed ID: 22375971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
    Al-Ali HK; Griesshammer M; Foltz L; Palumbo GA; Martino B; Palandri F; Liberati AM; le Coutre P; García-Hernández C; Zaritskey A; Tavares R; Gupta V; Raanani P; Giraldo P; Hänel M; Damiani D; Sacha T; Bouard C; Paley C; Tiwari R; Mannelli F; Vannucchi AM
    Br J Haematol; 2020 Jun; 189(5):888-903. PubMed ID: 32017044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ruxolitinib for myelofibrosis--an update of its clinical effects.
    Kantarjian HM; Silver RT; Komrokji RS; Mesa RA; Tacke R; Harrison CN
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):638-45. PubMed ID: 24238036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.
    Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger MW; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner EO; Lyons RM; Raza A; Vaddi K; Sun W; Peng W; Sandor V; Kantarjian H;
    Haematologica; 2015 Apr; 100(4):479-88. PubMed ID: 25616577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
    Verstovsek S; Mesa RA; Gotlib J; Gupta V; DiPersio JF; Catalano JV; Deininger MW; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner EO; Lyons RM; Paquette R; Raza A; Jones M; Kornacki D; Sun K; Kantarjian H;
    J Hematol Oncol; 2017 Feb; 10(1):55. PubMed ID: 28228106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.
    Harrison CN; Vannucchi AM; Kiladjian JJ; Al-Ali HK; Gisslinger H; Knoops L; Cervantes F; Jones MM; Sun K; McQuitty M; Stalbovskaya V; Gopalakrishna P; Barbui T
    Leukemia; 2016 Aug; 30(8):1701-7. PubMed ID: 27211272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
    Verstovsek S
    Postgrad Med; 2013 Jan; 125(1):128-35. PubMed ID: 23391678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ruxolitinib: a review of its use in patients with myelofibrosis.
    Plosker GL
    Drugs; 2015 Feb; 75(3):297-308. PubMed ID: 25601187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
    Bryan JC; Verstovsek S
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ruxolitinib: in the treatment of myelofibrosis.
    Yang LP; Keating GM
    Drugs; 2012 Nov; 72(16):2117-27. PubMed ID: 23061804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
    Verstovsek S; Kantarjian HM; Estrov Z; Cortes JE; Thomas DA; Kadia T; Pierce S; Jabbour E; Borthakur G; Rumi E; Pungolino E; Morra E; Caramazza D; Cazzola M; Passamonti F
    Blood; 2012 Aug; 120(6):1202-9. PubMed ID: 22718840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis.
    Jung CW; Shih LY; Xiao Z; Jie J; Hou HA; Du X; Wang MC; Park S; Eom KS; Oritani K; Okamoto S; Tauchi T; Kim JS; Zhou D; Saito S; Li J; Handa H; Jianyong L; Ohishi K; Hou M; Depei W; Takenaka K; Liu T; Hu Y; Amagasaki T; Ito K; Gopalakrishna P; Akashi K
    Leuk Lymphoma; 2015 Jul; 56(7):2067-74. PubMed ID: 25315076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.
    Verstovsek S; Gotlib J; Mesa RA; Vannucchi AM; Kiladjian JJ; Cervantes F; Harrison CN; Paquette R; Sun W; Naim A; Langmuir P; Dong T; Gopalakrishna P; Gupta V
    J Hematol Oncol; 2017 Sep; 10(1):156. PubMed ID: 28962635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
    Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
    Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I.
    Miller CB; Komrokji RS; Mesa RA; Sun W; Montgomery M; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):479-487. PubMed ID: 28606598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.